As of the latest Form 4 filed Jul 9, 2026.
What Recursion Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 30 most recent filings for RXRX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | Borgeson Blake Director | SSale | −40.0K | $3.96 | $159K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Dar Zavain Director | AAward | +5.11K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Li Dean Y Director | AAward | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-18 | Bumpus Namandje Director | SSale | −3.96K | $3.18 | $12.6K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Borgeson Blake Director | AAward | +88.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | HERSHBERG ROBERT Director | AAward | +88.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Michor Franziska Director | AAward | +88.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Sun Elaine D Director | AAward | +88.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Dar Zavain Director | AAward | +88.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Li Dean Y Director | AAward | +88.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Bumpus Namandje Director | AAward | +88.4K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Taylor Ben R Chief Financial Officer | FTax | −5.40K | $3.15 | $17.0K | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-05 | Khan Najat CEO and President | SSale | −23.6K | $3.58 | $84.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-05 | Gibson Christopher Director | SSale | −40.0K | $3.62 | $145K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-05 | Gibson Christopher, Director | CConvert | +40.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-03 | Bumpus Namandje Director | SSale | −4.39K | $3.54 | $15.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Borgeson Blake Director | SSale | −30.0K | $3.68 | $110K | Yes (planned) | Form 4 ↗ |
| 2026-05-27 | 2026-05-22 | Gibson Christopher Director | SSale | −40.0K | $3.08 | $123K | Yes (planned) | Form 4 ↗ |
| 2026-05-27 | 2026-05-22 | Gibson Christopher, Director | CConvert | +40.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Borgeson Blake Director | SSale | −30.0K | $3.52 | $106K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Gibson Christopher Director | SSale | −40.0K | $3.61 | $144K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Gibson Christopher, Director | CConvert | +40.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Gibson Christopher Director | SSale | −40.0K | $3.10 | $124K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Gibson Christopher, Director | CConvert | +40.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Borgeson Blake Director | SSale | −30.0K | $3.10 | $93.0K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-06 | Taylor Ben R Chief Financial Officer | FTax | −48.0K | $3.11 | $149K | No | Form 4 ↗ |
| 2026-03-25 | 2026-03-23 | Gibson Christopher Director | SSale | −40.0K | $3.25 | $130K | Yes (planned) | Form 4 ↗ |
| 2026-03-25 | 2026-03-23 | Gibson Christopher, Director | CConvert | +40.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Taylor Ben R Chief Financial Officer | SSale | −7.96K | $3.39 | $27.0K | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Taylor Ben R, Chief Financial Officer | FTax | −7.08K | $3.42 | $24.2K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also RXRX’s full analysis or the market-wide insider trading feed. The tabs above jump to RXRX’s other SEC data.
Source: SEC Form 4 filings for RXRX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.